Brief: Vyne Therapeutics Announces Results From Its Phase 2A Trial Of Fmx114 For The Treatment Of Mild-To-Moderate Atopic Dermatitis

YARROW BIOSCIENCE

10/08/2022 13:38

Aug 10 (Reuters) - Vyne Therapeutics Inc  VYNE.O :
    * VYNE THERAPEUTICS ANNOUNCES RESULTS FROM ITS PHASE 2A
TRIAL OF
FMX114 FOR THE TREATMENT OF MILD-TO-MODERATE ATOPIC DERMATITIS
    * VYNE THERAPEUTICS INC - STUDY VY2021-01 DID NOT MEET ITS
PRIMARY
ENDPOINT
    * VYNE THERAPEUTICS INC - EXPECTS TO REPORT CASH AND CASH
EQUIVALENTS OF APPROXIMATELY $43 MILLION AS OF JUNE 30, 2022
    * VYNE THERAPEUTICS INC - ENTITLED TO RECEIVE A $5.0 MILLION
PAYMENT IN JANUARY 2023 IN CONNECTION WITH SALE OF MST FRANCHISE

Source text for Eikon:  ID:nGNX3260rN 
Further company coverage:  VYNE.O 

 ((reuters.briefs@thomsonreuters.com;))